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Friend murine leukemia virus, which induces malignant erythropoiesis in mice, is 
a  complex containing spleen focus-forming virus  (SFFV)  I  and  lymphatic leukemia 
virus (LLV-F)  (1).  SFFV is defective and  is dependent upon its associated helper, 
LLV-F, which supplies type-specific virus envelope antigen (2, 3). At least two genes 
determine the host response to Friend leukemia virus (FV) complex. The Fv-1 gene 
controls host resistance to LLV-F and appears to be identical to the N-B locus con- 
ferring resistance to XC plaque formation in embryo cells by murine leukemia virus 
(4). The Fv-2 gene controls susceptibility to SFFV. Mice homozygous for resistance 
(Fv-2Tr),  including  those  of  strains  C57BL  and  C58,  are  completely resistant  to 
splenomegaly and erythroblastosis induced by most strains of the FV complex (SFFV 
[LLV-F]) (5). Such "resistant" mice are also refractory to the extremely suppressive 
effect of  the  FV  complex on  antibody formation  (6),  but  remain  sensitive to  the 
moderate and  transient suppression induced by LLV alone (1). Furthermore, since 
resistance to leukemia in Fv-2  ~  mice was not abrogated by treatment with cortisol 
(7)  or antilymphocytic serum  (8), it appeared that the Fv-2 resistance was not im- 
munologically  mediated by thymus-dependent (T) cells or bursa equivalent-dependent 
(]3) cells. 
Resistance to FV complex could be transferred to susceptible mice by bone marrow 
cell grafts (9,  10). Thus,  it appeared that Fv-2, the gene for resistance to leukemia, 
mediated its action through a  hemopoiefic cell which was either present in or could 
be generated from the bone marrow. It was assumed from the above experiments and 
other data (7, 8) that the hemopoietic cells through which resistance to leukemia was 
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manifested were the erythropoietic stem cells which are the target cells for FV-induced 
transformation. 
When analyzing studies on  the immunobiology of bone marrow transplantation, 
we were impressed by the similarity that exists between the ability of various strains 
of mice to reject allogeneic bone marrow grafts, and their ability to resist erythro- 
leukemia induced by FV (11). Thus, adult mice of the strains C57BL, B10.D2,  and 
C58,  which are good responders to most bone marrow allografts are also extremely 
resistant to Friend SFFV-induced erythroleukemia. Conversely, F,-288 mice, such as 
DBA/2, BALB/c, and 129 strain mice, are both poor responders to most bone marrow 
allografts (reference 12 and unpublished observations) and susceptible to SFFV. This 
.and other evidence presented here suggested to us that resistance to Friend leukemia 
and to hemopoietic allografts may be mediated by a  common effector system under 
Fv-2 genetic control. 
Immune cells responsible for the rejection of bone marrow allografts are thymus- 
independent  effector cells which  recognize  transplantation  antigens  that  are  ap- 
parently  restricted  to  primitive  hemopoietic  cells,  called  hybrid  or  hemopoietic 
histocompatibility (Hh)  antigens (12). Agents which suppress B  cells (cortisol) or T 
cells (rabbit antimouse thymocyte serum) do not affect these effector cells. However, 
89Sr,  a  radioactive bone-seeking isotope with a  half-life of 62  days, selectively sup- 
presses the ability of mice to reject hemopoietic cell grafts without affecting B  cells, 
T  "helper" cells, or T  cells involved in graft-vs.-host reactions (13). These ceils have 
been termed marrow-dependent effector (M) cells, since marrow appears to be their 
central lymphoid organ. In mice treated with 89Sr, the spleen takes over stem  cell 
function  (14),  and the erythropoietic progenitor cells, which are the target cells for 
FV,  are maintained  at  near  normal  numbers.  Antibody production  appears  to  be 
normal (15). 
The  experiments reported here were performed to test the hypothesis that 
the Fv-2 mediated genetic resistance to FV complex (SFFV[LLV-F]) is mediated 
through M  cells and not at the level of the erythropoiefic stem cells, i.e., "target 
cells." The results indicate that target cells from Fv-~" mice can be transformed 
by  FV under  appropriate conditions  and  the  selective abrogation  of  M-ceU 
function seems to confer susceptibility to mice otherwise genetically resistant 
to  FV  leukemia.  Preliminary  experiments  leading  to  this  work  have  been 
reported (11). 
Materials and Methods 
Mice.--Adult male mice of the strains C57BL/6J (B6), DBA/2J, B10.D2/nSn  (B10.D2), 
129/J, and C58/J were purchased from Jackson Laboratories, Bar Harbor, Maine. Mice were 
6- to 8-wk old when used in most cases. 
Virus and Virus Titration.--SFFV, as contained in the Mirand strain (16) of the FV com- 
plex, was originally obtained from Charlotte Friend (Mount  Sinai School of Medicine, New 
York) and has now undergone  over 200 cell-free passages in Ha/IClZ Swiss mice. More re- 
cently, it has been serially passaged through adult BALB/c mice and initiates infection with 
equal efficiency in DBA/2 and BALB/c mice, and is therefore designated as being NB-tropic. 
All SFFV preparations were titrated in vivo with the spleen focus assay method  (17). Briefly, 
1-ml samples of diluted SFFV were injected intravenously into susceptible mice. 9 days later, VINA¥  KUMAR~ MICHAEL  BENNETT~  AND  ROBERT  J°  ECKNER  1095 
their spleens were removed and fixed in Bouin's solution. Discrete foci on the splenic surface 
were counted by macroscopy, and virus titers (mean numbers of foci per spleen X  dilution 
factor) were expressed in focus-forming units (FFU)/ml, where 1 FFU is the amount of virus 
required to induce an average of I focus/spleen. 
Assay for Tumor Colony-Forming  Units (TCFU).--Transformation  of Pv-2  r, bone marrow 
cells after transplantation into the infected Fv-2  *s primary recipient was assayed as follows. 
Washed  spleen cells of  the Fv-2  s*  primary recipient were  infused into unirradiated adult 
Fv-2" secondary recipients which were syngeneic with the marrow donor. 9  days after cell 
transfer, the spleens were removed from the secondary recipients and fixed in Bouln's solution. 
The surface nodules were enumerated macroscopically and each nodule was taken to repre- 
sent one TCFU. The histologic examination of such nodules revealed foci of malignant ery- 
thropoiesis, which was unaffected  even if  the secondary recipients were previously hyper- 
transfused to suppress physiological erythropoiesis (18). Such loci of malignant erythropoiesis 
could not have been generated  by any free extracellular virus transferred along with  the 
spleen cells because the Fv-2  tt recipients are solidly resistant to focus formation by FV com- 
plex. A TCFU assay described earlier utilized Fv-2  rs (FI hybrids) as recipients (19). In such 
recipients which are only partially resistant to focus formation by SFFV, the splenic nodules 
represented not only TCFU but also some virus-induced foci. Therefore the assay described 
here is more discriminatory. Experiments described in this paper also rule out any contribution 
of the spleen cells of the primary recipient in generating the tumor colonies seen in the sec- 
ondary recipient. 
Administration  of Sgsr.--Doses of 25-100  t~Ci of 89Sr (Oak Ridge National Laboratory, 
Oak Ridge, Tenn.) were infused intravenously on two separate occasions 4 wk apart.  Mice 
were used for experiments 3-5 wk after the last injection. This protocol successfully prevents 
otherwise genetically resistant mice from rejecting incompatible parental strain or allogeneic 
marrow cell grafts (13). 
Cdl Transfer  Procedures.--The methods of harvesting, counting, and intravenous infusion 
of marrow and spleen cell suspensions have been described (12). When more than l0  T nucleated 
cells/inoculum were to be infused, 50 U of heparin were added to each 5 ml of cell suspension 
to prevent embolic death.  In some experiments the spleen cells were washed  once in a  re- 
frigerated centrifuge in 15-ml vol at 800 g for 10 rain. 
Cytdogy.--Differential  cell counts of imprints of the cut surfaces of spleens stained with 
Wright's stain were  performed  in  three  experiments.  In  another  experiment,  differential 
counts of paraffin sections stained with hematoxylin and eosin were performed. The purpose 
of these cytological studies was to determine the percentage of morphologically identifiable 
erythropoietic cells containing a  nucleus, i.e., proerythroblast to normoblast. At least 1,000 
nucleated cells/spleen were counted to obtain the values presented. 
Suppression  of Physiological  Erythropoiesis  by Hypertransfusion.--In  one experiment, B6 
mice treated with S9Sr as well as control B6 mice were infused intravenously with 1 ml of 
whole mouse blood on the 5th and 6th day after infection (or not) with FV. The spleens of 
these mice were removed for assays 3 days after the second infusion of blood and 9 days after 
infection. 
Immunizations and Assays for Antibody-Forming  Cdls.--Mice previously treated with Sgsr 
and infected (or not) with FV were injected intravenously with 5 X  l0  s sheep red blood cells 
(SRBC), 4  days later,  the spleens were removed and spleen cell suspensions O.001  spleen 
equivalent) were assayed for anti-SRBC hemolytic plaque-forming cells (PFC), using a modi- 
fication of the Jerne technique (7). 
Protocol  Involving  Transplantation  of  Resistant  Marrow Cdls  into  Infected  Susceptible 
Hosts.--Genetically  susceptible Fv-2  ~s mice were infected with 103 FFU of NB-tropic FV 
complex 4 days before exposure to lethal doses of T-rays (860 R) and intravenous infusion of 
genetically resistant Fv-2"" marrow cells (Fig.  1).  5-7 days later, the spleens of the primary 
hosts were assayed for the presence of SFFV and SFFV-induced tumor cells (TCFU). Spleen 1096  S%r  SUPPRESSION  OF  GENETIC  RESISTANCE  TO  LEUKEMIA 
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Fro.  1.  The experimental design to study transformation of B10.D2  bone marrow cells 
(Fv-grO. Susceptible DBA/2 (Fv-2*O mice were infected with 10  a FFU of FV. 4 days later 
they were lethally irradiated and grafted with 10  s or 10  7 B10.D2 bone marrow cells. 5-7 days 
later,  the spleens of the DBA/2 primary recipient mice were removed.  Spleen cell free ex- 
tracts were assayed for virus content by the spleen focus assay in DBA/2 mice. Spleen cells 
were assayed for B10.D2 TCFU by transplanting the cells into uuirradiated adult B10.D2 
secondary recipients. 
cell suspensions were washed once; various dilutions of the supernate were assayed for content 
of infectious SFFV by injecting the material into susceptible DBA/2 mice. The spleen cells 
(1/~ or 1/~ spleen equivalent) were infused into unirradiated secondary recipient mice (Fv-2  rr) 
syngeneic with marrow donor 1  o assay for TCFU. 
RESULTS 
Abrogation of Genetic Resistance to Friend Leukemia Virus by sgsr Treatment.- 
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be mediated by an effector system common with that responsible for rejection 
of bone marrow allografts (11),  the first set of experiments were designed to 
ask the question whether  administration of 89Sr which selectively abrogates 
the ability of mice to reject allogenic bone marrow would also abolish genetic 
resistance to FV leukemia. In a preliminary experiment, four B6 mice treated 
with 89Sr were infected with 100 FFU of FV complex and were killed 9 days 
later. Their spleens were moderately to severely enlarged. On fixation in Bouin's 
solution, no discrete foci of tumor cells could be seen grossly, since the entire 
surface of the spleens was bright yellow, as are individual tumor loci. However, 
microscopic examination of the enlarged spleens showed great expansion of the 
red pulp and almost complete effacement of the white pulp by large, primitive 
erythroid cells  (so-called "Friend cells"). There were abundant mitoses and 
differentiated erythroid cells  (normoblasts) with pyknotic nuclei. Since spleen 
foci were not countable, only histological evidence indicated that 89Sr treatment 
abrogated the resistance of Fv-2  ~' mice to malignant erythropoiesis. 
In subsequent experiments,  therefore, evidence for leukemia induction in- 
cluded recovery of infectious SFFV and induction of erythropoietin-independ- 
ent,  i.e.,  malignant,  erythropoiesis. Polycythemia induced  in  the  test mice 
would be expected to suppress physiological erythropoiesis but not malignant 
erythroblastosis induced by SFFV (18).  The spleens of mice treated with SgSr 
and infected with FV were enlarged, resembling those seen in the earlier experi- 
ment, while the spleens of normal B6 mice infected with FV were unaffected. 
Microscopic examination of the spleens showed extensive malignant erythro- 
poiesis  in  89Sr-treated  mice  after  FV  infection, despite  the  fact  that  these 
animals were polycythemic (Fig. 2 a). This was also reflected in the greater 
than 90% count of erythroid cells  (Table I). Erythropoiesis in the spleens of 
8~Sr-treated mice not infected with FV and in normal B6 mice infected with FV 
was almost completely suppressed  by hypertransfusion, indicating a  lack of 
malignant erythropoiesis. The splenic histology of B6 mice treated only with 
89Sr did reveal extensive myelopoiesis (Fig. 2 b); this was expected, since the 
spleens of such mice had taken over all stem cell functions of the mouse (14). 
A large amount of SFFV was recovered from the spleen and plasma of mice 
treated with 89Sr and infected with FV, whereas no detectable virus could be 
recovered from the normal B6 mice infected with FV at the dilution tested 
(Table I). 
These results were consistent with the concept that M  cells suppressible by 
89Sr are responsible for the genetic resistance of B6 mice to FV as well as for 
the genetic resistance to most bone marrow allografts (13). To seek confirmation 
of this apparent association between resistance to marrow allografts and re- 
sistance to malignant erythropoiesis, B6 mice were injected with 0, 25, 50, or 
100 #Ci of 89Sr twice at a l-too interval. 5 weeks after the second injection, the 
mice were infected with 75 FFU of NB-tropic FV complex. The spleens  were 
removed 9 days later. Imprints were stained with Wright's stain to determine 1098  S9Sr SUPPRESSION  OF  GENETIC  RESISTANCE  TO  LEUKEMIA 
FIG.  2.  (A)  Section from spleen of polycythemic C57BL/6 mouse treated with sgsr and 
later infected with FV. The entire spleen is filled with erythroid cells, which efface the white 
pulp. The pt4_mitive erythroid cells (Friend cells) are large, have vesicular nuclei, and promi- 
nent nucleoli. The smaller, mature normoblastic erythroid cells have dark pyknofic nuclei. 
Numerous mitotic figures (arrows) could be seen (H and E  X  430).  (B) Section from spleen 
of polycythemic C57BL/6 mouse treated with 89Sr but not infected with FV. Megakaryocytes 
and granulocytic cells at various stages in differentiation were the predominant cells.  Only 
rare erythroid cells were seen. These cells filled the subcapsular zone and the red pulp,  but 
did not efface the white pulp (H and E  X  430). VINAY  KUMAR,  MICHAEL  BENNETT,  AND  ROBERT  J.  ECKNER  1099 
TABLE I 
Effect of SgSr on Genetic Resistance of C57BL/6 Mice to FV-lnduced Malignant  Erythropoicsis 
Treatment  Infection  Erythroid cells in spleen  Virus recovery 
with s~Sr* with FV*  Polycythemic  Not polycythemic  Plasma:~  Spleen§ 
%  %  FFU/ml  FFU/spleen 
q-  q--  95  (3)¶  91  (4)  >105  (7)  >10  s  (7) 
q-  --  3  (2)  NT[[  0  (4)**  NT 
--  q-  1.5  (3)  12  (4)  0  (7)  0  (3) 
--  --  0.3  (2)  13.2  (4)  NT  NT 
* C57BL/6 adult mice with or without prior treatment with 89Sr were infected with 100 
FFU of NB-tropic FV complex. 9 days later  all  mice were sacrificed. Plasma  and spleens 
were removed for various assays at this time. 
Plasma was tested for content of FV complex by injection of a 1 ml of 1:1,000 dilution 
into DBA/2 mice. 
§ Splenic virus  content was  estimated  by mincing spleens in Eagle's MEM  and  then 
assaying the first washing (1 ml of 1 : 1,000 dilution) for virus in DBA/2 mice. 
¶ Numbers in parentheses indicate the number of animals used. 
][ NT, not tested. 
** To exclude activation  of a latent virus in mice by treatment with SOSr, plasma samples 
from four such animals were assayed for presence of any FV complex before further treat- 
ment. Undiluted 0.1-ml plasma from each animal was injected into DBA/2 mice. 
the percentage of erythroid cells and the washed spleen cell  supernatent fluids 
were assayed for SFFV. The results are presented in Table II. 
The amount of virus recovered from B6 mice was a function of the dosage of 
S9Sr. Similarly, the percentage of erythroid cells in the spleen increased as the 
dosage of sgSr increased. 
Susceptibility  to  Suppression  of Antibody Synthesis  Induced  by FV.--Four 
8°Sr-treated  and four of eight normal B6 mice were infected  with  50 FFU of 
NB-tropic FV complex. 7 days later all 12 mice were immunized with 5  X  10  s 
SRBC intravenously to determine  if FV would immunosuppress mice treated 
with saSr. On the llth day after infection with FV (4 days after immunization 
with SRBC), all the animals were killed and a direct PFC assay was performed 
with the spleen cells of all the mice to measure the primary IgM cellular anti- 
body response to SRBC. 
B6 mice treated  with  sgSr  and  infected  with  FV  complex generated  much 
fewer  IgM  PFC  against  SRBC  than  uninfected  B6  mice  (P  <  0.001)  and 
fewer PFC  than infected B6 mice not treated  with sgSr  (0.001  <  P  <  0.01) 
(Fig.  3).  The  latter  mice  were  moderately,  but  significantly  (0.001  <  P  < 
0.01), immunosuppressed,  presumably because they were successfully infected 
with the NB-tropic LLV in the virus preparation  (1). 
To confirm and extend previous data  (13,  15) indicating that sgSr does not, 
in  itself,  suppress  antibody production  under  the  conditions  used  here,  four 
additional  mice were treated  with sgSr, as described above. These mice and 8 
age-control mice were  immunized  with  5  X  l0  s SRBC,  and  the  spleen  cells 1100  SgSr SUPPRESSION  OF  GENETIC  RESISTANCE  TO  LEUKEMIA 
TABLE II 
Effect of Varying Doses of SgSr on Genetic Resistance  of C57BL/6 Mice to FV* 
Dose of ~Sr  Erythroid cells in spleen  SFFV recovered/spleen  ()< 15)$ 
~Ci  %  Mean =1= SE 
0  13.5  0.6  =i=  0.39 
25  32  15.2  -4-  2.43 
50  90  69.8  -4-  5.64 
100  93.5  76.4  -1-  4.15 
* C57BL/6 adult mice were injected with different doses  of SgSr on two occasions  4 wk 
apart;  5 wk after the last injection of 89Sr they were infected with 75 FFU of FV.  9 days 
later all mice were sacrificed  and spleens were removed for various assays.  Only when the 
virus yield was 8-10 times greater than the input dose, it was considered that active virus 
replication occurred in the spleen. 
:~ Results are expressed as virus/spleen X  15, since supernate  from 1/~5 spleen fractions 
was used to infect susceptible mice for virus titration. 
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Fio.  3.  Anti-SRBC  antibody  synthesis in  B6 mice infected with FV,  with  or  without 
prior treatment with 89Sr. Four each of 89St-treated and normal B6 mice were infected with 
FV (50 FFU). 7 days later these and four uninfected control B6 mice were immunized with 
SRBC. 4 days after immunization a direct PFC assay was performed. Result: FV markedly 
suppressed  antibody  synthesis  in  B6  mice  treated  with  SgSr. Blank  column,  uninfected; 
stippled column, FV infected, but not treated with 89Sr; and diagonal column, 89Sr-treated 
and infected with FV. 
were  assayed  for  PFC  4  days  later.  The  mean  (4-  SE)  numbers  (X  1@)  of 
PFC/spleen  were 69.7 4-  21.5  and 39.0 4-  3.6 in mice treated with 89Sr and in 
control mice, respectively (0.1  <  P  <  .2).  Thus,  sgSr alone does not suppress 
antibody production. 
In  some of the  above  experiments,  spleen  cells from  B6 mice treated  with 
89Sr and infected with FV were transplanted into adult unirradiated  B6 mice to VINA¥  KUMAR,  MICHAEL  BENNETT,  AND  ROBERT  J.  ECKNER  1101 
see if tumor colonies would develop in the recipient mice by proliferation of 
the transformed cells from the 89Sr-treated  donor. No discrete tumor colonies 
were seen in the spleens of recipient B6 mice. 
Transformation  of Fv-2  "r BIO.D2  Bone Marrow Cells Grafted into  Irradiated 
Fv-2 ~8 DBA/2  Recipient  Mice  Previously  Infected  with  FV  Complex.--Either 
one of two different hypotheses could explain why sgSr had rendered genetically 
resistant C57BL/6 mice susceptible to the leukemogenic action of FV. 89Sr may 
have affected the susceptibility of otherwise genetically resistant erythropoietic 
target cells  to malignant transformation by FV. In contrast, 89Sr may have 
affected a regulatory cell of the hemopoietic system that prevents transforma- 
tion of target cells  or subsequent proliferation of transformed cells.  To  test 
whether or not "resistance" genes, e.g., Fv-2,  primarily affect target cells, we 
exposed marrow erythropoietic target cells of Fv-2  ~" mice to the hemopoietic 
environment in Fv-2*" mice which is compatible with malignant erythropoiesis 
(Fig. 1). If genetic resistance is primarily a property of target erythropoietic 
stem cells, malignant transformation should not occur. However, if such genes 
affect hemopoietic stem cell regulation, malignant transformation may indeed 
occur. Therefore, Fv-2 *~ DBA/2 adult mice were infected with 103 FFU of FV 
complex 4 days before lethal irradiation (860 R) and transplantation of inocu- 
lum of 10  e or 107 marrow cells from adult Fv-2" B10.D2 donor mice (Fig. 1). 
DBA/2 and B10.D2 mice share the H-2  d alleles.  5-30 days later, the spleens 
of the primary recipient DBA/2 mice were assayed for content of SFFV and 
TCFU. The results are presented in Table III. 
Bone marrow cells (107) of B10.D2 origin supported both SFFV replication 
and  generated TCFU  (Exp.  1,  Table III).  However,  the  TCFU  generated 
were too numerous to count accurately. No TCFU or SFFV were recovered 
when the primary recipients were B10.D2  rather  than DBA/2 mice. In the 
subsequent experiments, only 106 donor marrow cells  were grafted and only 
1/~ spleen equivalent of cells  (instead of 1~ in Exp. 1, Table III)  was retrans- 
planted.  B10.D2  bone marrow-derived cells  growing in  spleens of irradiated 
and infected DBA/2 mice again supported both virus replication and yielded 
transformed TCFU (Exp. 2, Table III). In a control group of primary recipient 
mice which  were not infected, but  transplanted  with B10.D2  bone marrow 
cells, no TCFU were recovered. Also the participation of transplanted B10.D2 
bone marrow cells in the generation of TCFU was indicated by the failure to 
recover TCFU from spleens of DBA/2 primary recipients, previously infected, 
but  not  transplanted  with  B10.D2  bone marrow  cells  (Exp.  2,  Table III). 
Tumor colonies in B10.D2 secondary hosts were seen as slightly raised bright 
yellow nodules at the surface of the spleen (Fig. 4). Histologic examination of 
the secondary recipient spleens, revealed the typical picture of Friend erythro- 
leukemia, with colonies of transformed erythroid cells under the capsule and 
invading the white pulp. It may be re-emphasized that FV by itself does not 
induce erythroleukemia in B10.D2 mice. These results indicate that the Fv-2 1102  Sgsr SUPPRESSION  OF  GENETIC  RESISTANCE  TO  LEUKEMIA 
TABLE III 
Transformation of BIO.D2 Bone Marrow Cells 
Exp. 
:No. of cdls 
trans- 
planted 
from a 
BI0.D2 
marrow 
donor 
10  7 
10  7 
10  7 
10  6 
106 
No cells 
10  6 
10  6 
10  6 
DBA/2 primary recipients* 
Virus treatment 
SFFV(LLV) 
No virus 
SFFV (LLV) :~ 
SFFV(LLV) 
No virus 
SFFV(LLV) 
SFFV(LLV) 
SFFV(LLV) 
SFFV(LLV) 
SFFV recovered 
FFU/Spleen 
400  (5)§ 
0  (5) 
0  (4) 
>l,000  (7) 
0  (5) 
0  (5) 
NT 
NT 
NT 
Interval in 
days between 
transplan- 
tation of donor 
marrow cells 
and retrans- 
plantation of 
primary 
recipient 
spleen cells 
5 
15 
30 
B10.D2 secondary recipients 
Tumor colonies/ 
spleen (X 8) 
Mean  4-  SE 
>ioo (5) 
0  (5) 
0  (4) 
23.4  4-  3.3  (7) 
0  (5) 
0  (5) 
35.2  4-  6.4  (5) 
27.0  4-  5.4  (5) 
0  (5) 
SFFV recovered 
FFU/Spleen 
>500  (s) 
0  (5) 
NT¶ 
>500  (7) 
NT 
NT 
NT 
NT 
NT 
* Primary recipient mice were infected with  103 FFU of NB-tropic  FV complex. They 
were irradiated  4 days later and transplanted with B10.D2 bone marrow cells. On day 5, 7, 
15, or 30 after transplantation, the primary recipient spleen cells were harvested and washed 
once in Eagle's MEM. The supernatant fluid was assayed for FFU in DBA/2 mice and the 
cells were assayed for TCFU by retransplanting ~  (Exp. 1) or 1/~ (Exp. 2 and 3) fraction 
of the primary spleen into adult unirradiated  B10.D2 mice. 9 days later the B10.D2 see- 
ondary redpient mice were killed and the spleens were fixed in Bouin's solution and examined 
for tumor colonies. 
In this  group the primary recipients were B10.D2 mice infected with SFFV(LLV) 4 
days before irradiation and transplantation of B10.D2 bone marrow cells. 
§ Numbers in parentheses indicate number of animals used. 
¶ NT, not tested. 
gene does  not  control susceptibility of  erythropoietic "target"  stem  cells  to 
malignant transformation by FV. 
In Exp. 3, Table III, the intervals between grafting of the resistant donor 
marrow cells and the assay for TCFU generated in the DBA/2 recipient spleens 
was 5, 15,  or 30 days. If Fv-2 controls the functions of M  cells or other hemo- 
poietic cell types, we reasoned that resistance to leukemia may develop in the 
bone marrow chimeras as these cells were generated by stem cells in the resistant 
bone marrow inoculum. There was no significant difference in the number of 
tumor colonies generated in the secondary recipients, whether retransplantation 
of DBA/2 spleen cells was done on day 5 or 15  (Exp. 3, Table III). However, 
when B10.D2 marrow cells were allowed to develop in DBA/2 spleens for 30 
days before the retransplantation was performed, no TCFU could be recovered VINAY KUMAR, MICHAEL BENNETT, AND ROBERT J. ECKNER  1103 
FIG. 4.  Spleens fixed in Bouin's solution taken  from B10.D2 secondary recipients. The 
upper spleen is from a B10.D2 mouse which received a spleen cell transplant from a  DBA/2 
primary recipient, previously infected and transplanted with B 10.D2 bone marrow cells (out- 
lined in Fig. 1). It shows numerous slightly elevated pale tumor colonies. The lower spleen, 
which is devoid of any tumor colonies, is from a control group in which the B10.D2 secondary 
recipient was transplanted  with  spleen cells from a  DBA/2  primary  recipient previously 
infected with FV, but not given the B10.D2 bone marrow cells (X 4.5). 
as  indicated  by  total  absence  of  tumor  colonies  in  the  secondary  recipient 
spleens. 
Certain control experiments were performed to further establish that Fv-2  ,r 
B10.D2 and not FV-2** DBA/2 TCFU were being produced and detected under 
these experimental conditions  in  the secondary recipient.  A  group of DBA/2 
mice were infected with  1@ FFU of NB-tropic FV complex and their spleens 
were removed 9 days later when massively enlarged with erythroleukemic cells. 
The spleen cells were harvested from these DBA/2 mice, were washed to remove 
excessive  extracellular  virus,  and  were  transplanted  (~/~ spleen  equivalent) 
into five adult unirradiated B10.D2 recipients. 9 days later the B10.D2 recipient 
spleens were removed, fixed in Bouin's solution, and examined for TCFU. No 
tumor colonies were seen in any of the spleens of the five B10.D2 mice. Thus, 
Fv-2  r~ B10.D2 mice did not support the proliferation of TCFU of DBA/2 origin. 
In  another  experiment  we  followed  the  experimental  protocol  outlined  in 
Fig.  1 except that the bone marrow donors of 10 8 cells/inoculum were DBA/2 
mice instead  of B10.D2.  The  primary recipients  were  DBA/2  mice.  5  days 
later spleen cells (after three  washes)  of the primary recipients were retrans- 1104  Sgsr  SUPPRESSION  OF  GENETIC  RESISTANCE  TO  LEUKEMIA 
planted (~ spleen equivalent) into both DBA/2 and B10.D2 secondary recipi- 
ents.  While  DBA/2  secondary  recipients  supported  the  growth  of  DBA/2 
TCFU generated in DBA/2 hosts (there were 50-100 tumor colonies/secondary 
recipient spleen), B10.D2 secondary recipients did not. In this experiment the 
surface nodules seen on the DBA/2 secondary recipient spleens would certainly 
include some foci formed by the transfer of a  small  amount of extracellular 
virus carried along with the spleen cells in addition to tumor colonies generated 
by transformed DBA/2 cells. However, the total absence of tumor colonies in 
B10.D2 secondary recipients, clearly proves the point that TCFU of DBA/2 
origin when carried over into B10.D2 secondary recipients cannot proliferate 
to produce tumor colonies. 
If  the TCFU generated under these experimental conditions  are of donor 
(B10.D2)  origin,  a  linear  relationship  should  exist between  the  numbers  of 
TCFU generated and number of marrow cells transplanted  within  a  certain 
range of cell inoculum sizes. Therefore, infected and irradiated DBA/2 primary 
recipient mice were infused with 1.5, 4.5, or 13.5  X  105 B10.D2 marrow cells. 
Spleen cells (~ spleen equivalent) were assayed for TCFU in B10.D2 secondary 
recipients  5  days  after  marrow  transplantation.  Under  these  conditions,  a 
linear relationship between inoculum size and TCFU generated was obtained 
(Fig. 5). 
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FIG.  5.  Relationship  between  the  number  of  B10.D2  bone  marrow  cells  injected  into 
previously infected I)BA/2 primary recipient and  the number of  tumor colonies generated 
upon transplantation of spleen cells from the DBA/2 recipient into adult unirradiated B 10.D2 
secondary host (see Fig. 1 for details). Result: a linear relationship exists between the cell 
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Preliminary experiments (not reported here) with other strain combinations 
confirmed the findings obtained with B10.D2  and DBA/2.  B6  (Fv-2"O  bone 
marrow  cells  could  be  successfully transformed by  grafting into previously 
infected leukemic  and  irradiated  histocompatible  129/J  (Fv-2  ~8)  mice,  and 
C58/J marrow cells could be transformed by transplantation into previously 
infected (C58  ;<  C3H)F1 (Fv-2  ~) primary recipients. Whereas discrete tumor 
colonies could not be seen in the spleens of B6 secondary recipient mice, histo- 
logic evidence of transformation was obtained. The B6 and C58 marrow cells 
also supported extensive SFFV replication under these conditions. 
DISCUSSION 
The  occurrence of  splenomegaly with  the  histologic picture  of malignant 
erythropoiesis independent of erythropoietin, the synthesis of infectious SFFV 
recovered from the plasma and spleen supernatant fluids, and the severe sup- 
pression  of  antibody formation indicate  that sgSr treatment overcomes  the 
genetic resistance of B6 mice to FV leukemia. Recovery of infectious SFFV 
and percentage of neoplastic erythroid cells in the spleens was a function of the 
dosage of sgSr administered. This finding is similar to the dose-related suppres- 
sion of marrow allograft rejection by sgSr (13). 
Since a  similar treatment with sgSr also suppresses the ability of "good re- 
sponder" mice to reject bone marrow allografts, one of the logical conclusions 
is that the cells responsible for expression of genetic resistance to this leukemia 
are the same as the M cells involved in rejection of hemopoietic allografts (13). 
Besides susceptibility to SgSr, some other properties of M  cells also seem to go 
along with their suggested role in mediating resistance to FV complex. Thus, 
resistance to FV complex is not abrogated by thymectomy followed by irradia- 
tion  and marrow reconstitutlon  (unpublished  results),  treatment with  anti- 
lymphocytic serum (8),  or cortisol (7); such is also the case with rejection of 
bone marrow allografts (12).  Before 21 days of life, when the ability to reject 
bone marrow allografts is still not developed  (12),  mice are  also exquisitely 
sensitive  to  leukemia viruses  (20).  Even  infant B6  mice  infected with  FV 
develop splenomegaly and high titers of circulating FV, both of which regress 
after the first 3 wk of life (unpublished observations). 
The inability to see discrete tumor foci in adult B6 mice treated with 89Sr 
is interesting. A similar situation exists in the case of infant mice less than 21 
days old, in which erythropoiesis and virus replication occur but no discrete 
loci can be seen (unpublished observations). Perhaps extensive myelopoiesis, 
which occurs in the spleens of both infant mice and adult mice treated with 
89Sr, prevents the expression of malignant erythropoiesis in the form of discrete 
foci. 
One of the natural corollaries of the postulated mechanism of action of 89Sr 
would be that genetic resistance to FV leukemia is not due to resistant erythro- 
poietic target  cells  as had been previously suggested  (7,  9).  The  successful 
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mice strengthens and complements the conclusion that resistant mice do indeed 
possess susceptible target cells. These target cells are normally prevented from 
being rendered leukemic or proliferating by some influence of the 89Sr-sensitive 
population of effector cells,  i.e.,  M  cells.  These observations also imply that 
target cells of susceptible mice become transformed and continue to proliferate 
due to the genetically determined inability of their M cells to exert surveillance. 
Since  successful  transformation  of  resistant  B10.D2  target  cells  occurred 
during the first 15 days after marrow transplantation  (Table III), it follows 
that  the hemopoietic cells conferring resistance either were not immediately 
transplantable or were not present in bone marrow cell suspensions. We have 
tried unsuccessfully several times to adoptively transfer immediate resistance 
to bone marrow allografts with marrow, spleen, or lymph node cell suspensions, 
and  tentatively conclude that  these effector cells are not immediately trans- 
plantable  (unpublished  observations).  However,  precursors  of  M  cells  are 
transplantable as is indicated by the observation that the ability to reject bone 
marrow grafts can be detected in poor responder 129/J mice if 3 wk or more 
are allowed to pass after transplantation of bone marrow cells from good re- 
sponder B6 mice (12). In the present experiments, therefore, when the retrans- 
plantation of primary recipient spleens was delayed until 30 days, no TCFU 
could be recovered. This finding could be explained by the generation of geneti- 
cally resistant M  cells from their precursors in the B10.D2 bone marrow inocu- 
lum between 15 and 30 days. Thus, observations that resistance to FV leukemia 
could be transferred to susceptible strains by means of bone marrow cell grafts 
(9,  10)  can now be better explained by the development in the recipients of 
resistant effector M  cells.  This latter observation suggests that marrow grafts 
from histocompatible but genetically resistant donors may help cure leukemia 
in susceptible recipient mice. This possibility is now being tested. 
In two separate experimental conditions (Table I  and III), transformed B6 
cells failed to produce grossly discrete tumor colonies in the spleen upon trans- 
plantation  into unirradiated  adult  B6 mice,  while  transformed B10.D2  and 
C58 cells did produce discrete colonies. The B6 spleens fixed in Bouin's con- 
tained ill-defined bright yellow "areas" which histologically revealed malignant 
erythropoiesis. B6, B10.D2, and C58 mice are all Fv-2  ~"  but differ at the H-2 
locus. It is conceivable that the gene for resistance to FV leukemia associated 
with the H-2  b allele (5) affects the development of tumor colonies in Fv-2  ~ mice. 
The mechanism by which M  cells confer resistance to FV leukemia is not 
entirely clear. As mentioned earlier, M  cells recognize Hh  antigens expressed 
normally on primitive hemopoietic cells.  The expression of a  certain type of 
Hh  antigen was  observed to be increased  10-fold on Friend erythroleukemic 
progenitor cells; that event appeared to occur almost simultaneously with the 
transforming events (21). It may be speculated that in resistant mouse strains 
the transformed cells with increased Hh expression on the surface are rejected 
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Another testable hypothesis developed during this study relates to the nature 
of the Fv-2 gene. Since the Fv-2 gene seems to mediate its effect by controlling 
properties of the M  cells, it may be identical to one of the immune response 
genes which affect M-cell reactivity in rejection of marrow allografts (12,  22, 
23).  Although the strain distribution of "good responders" to marrow grafts 
and Fv-2" mice is similar (11),  the real test for this hypothesis would be to 
compare the relative abilities of C57BL/6 (good responders  and Fv-2  ~r)  and 
C57BL/6. Fv-28~ mice to reject marrow allografts. The latter congenic C57BL 
mice would have  the Fv-2  susceptible  gene serially backcrossed  onto  them. 
Breeding of such congenic mice is now being undertaken. 
From the experiments reported here, the 89Sr-sensitive population of effector 
cells  does seem to be very important in mediating genetic resistance to Friend 
leukemia. However this does not exclude that other immunocompetent cells 
belonging to the T- and B-cell systems may also contribute to protection from 
leukemia in the resistant strains. In this connection, preliminary experiments  2 
indicate that thymus cells  may also be involved in genetic resistance. Thus 
mitogenic response of T  cells from a number of Fv-2  rr donors is not suppressed 
by FV in vitro, while that of T  cells from susceptible strains is significantly 
depressed.  Also  simultaneous  transplantation  of  thymus  and  bone  marrow 
cells from resistant donors into infected susceptible recipients, seems to offer 
partial protection to the resistant bone marrow cells from transformation. The 
exact relationship between thymus cells and M cells in mediating resistance to 
this leukemia is under investigation. 
SUMMARY 
Resistance  to  malignant  erythropoiesis  induced  by  Friend  spleen  focus- 
forming virus and resistance to marrow stem cell allografts are under genetic 
control. Strains of mice, e.g., C57BL/6 and B10.D2, which are homozygous for 
resistance at the Fv-2 locus, are also good rejectors of most bone marrow allo- 
grafts. 89Sr, a bone-seeking isotope, irradiates marrow but not other lymphoid 
organs and abrogates resistance to marrow allografts without suppressing T- or 
B-cell functions. Thus, marrow-dependent effector cells (M cells) seem to resist 
allogeneic stem cells. To test if the genetic resistance to Friend virus (FV) is 
also mediated by M cells, B6 mice were treated with 89Sr using a dosage schedule 
known to abrogate resistance to allogeneic marrow cells. 9 days after FV infec- 
tion of such mice, the spleens showed malignant erythroblastosis which could 
not be  suppressed  by prior  hypertransfusion, a  procedure  which  suppresses 
physiologic erythropoiesis. Such 89Sr-treated  B6 mice also supported extensive 
virus  replication,  while  control mice  did  not.  FV  markedly suppressed  the 
ability of SgSr-treated  B6  mice to produce  antisheep red blood cell  (SRBC) 
2 Vinay Kumar, Michael Bennett, Tin Han, and Robert J. Eckner.  Mechanisms of genetic 
resistance to Friend murine leukemia virus. II. Role of thymus cells. Manuscript in prepara- 
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antibodies, a feature seen normally only in genetically susceptible mice. Thus, 
SgSr-treated B6 mice behaved in  these respects as if they were susceptible to 
FV. When increasing doses of SgSr were administered to B6 mice, a dose-related 
loss of resistance to FV was seen. Therefore, it appears that 89Sr-sensitive M 
cells mediate the genetic resistance to FV. 
The results of experiments with 89Sr indicated that genetically resistant mice 
would be expected to possess target cells which are susceptible to transformation 
by FV. To verify this corollary, bone marrow cells from B 10.D2  (Fv-2  r~) mice 
were  transplanted  into  previously  infected  and  lethally  irradiated  DBA/2 
(Fv-28~) recipients which share the same H-2  ~ alleles. 5-15 days later, the spleens 
of  DBA/2  primary recipients  yielded  transformed  cells  which  were  capable 
of producing  splenic tumor colonies upon  transplantation  into  adult,  unirra- 
diated B10.D2  secondary recipients. Various control experiments clearly indi- 
cated that the tumor colonies so induced were of B10.D2 marrow origin. This 
indicated that B10.D2 stem cells could be transformed when allowed to interact 
with  FV  in  the  spleens of susceptible DBA/2  mice. However,  30  days after 
transplantation of B10.D2 bone marrow cells into DBA/2 recipients, no trans- 
formed cells were detected.  Apparently,  in  the 30-day interval precursors in 
the B10.D2  marrow gave rise to mature M  cells which  resisted the leukemic 
process.  Since  M  cells  recognize  hybrid  or  hemopoietic  histocompatability 
antigens  expressed on primitive normal and  transformed hematopoietic cells, 
we  suggest  that  M  cells  may exert  surveillance  by rejecting  leukemic  cells. 
Thus, marrow transplantation  from genetically resistant donors may provide 
a new mode of treatment for leukemia, by providing precursors of M  cells and 
other immunocompetent cell types. 
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